Thirteen drug-resistant epilepsy patients received loreclezole as add-on therapy. The trial lasted 6 months. Loreclezole was dosed to reach a target plasma concentration between 1 and 3 mg/l. The seizure frequency in the total group decreased by 23%. A reduction of 50% or more was observed in four p
Single-dose efficacy evaluation of loreclezole in patients with photosensitive epilepsy
โ Scribed by J. Overweg; F. De Beukelaar
- Publisher
- Elsevier Science
- Year
- 1990
- Tongue
- English
- Weight
- 563 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0920-1211
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u
The effect and safety of loreclezole were evaluated during a long-term follow-up trial targeting higher plasma concentrations than those of the preceding controlled trial. The result is better than in the double-blind trial, in which loreclezole doses were administered to reach plasma concentrations